million phase choic start data
proteostasi end cash million phase choic hit-cf trial
complet enrol cystic fibrosi patient trial conduct
cf europ evalu person medicin approach next step evolut
treatment cf given heterogen natur vari respons current
therapi choic expect begin dose preliminari data
could acceler ema approv proteostasi proprietari triplerx dirocaftor
posenacaftor nesolicaftor proteostasi intend initi phase
triplerx trial homozyg patient later year depend fund
reiter overweight lower price target
phase choic trial fulli enrol hit-cf european research project
organ univers medic center utrecht netherland
mutat cftr caus cf common observ
least one allel patient one goe list cftr mutat becom
rarer cf commun long need solut treat patient hit-cf
attempt address challeng deriv organoid model intestin
elig cf patient model predict individu patient respons
therapi base organoid activ patient enrol appropri clinic
studi earli respons seen organoid profil pti triplerx drug
support patient roll choic clinic portion studi evalu clinic
benefit chang sweat chlorid trial fulli enrol
cf patient dose portion studi start preliminari
data expect set basi potenti file novel
regulatori pathway see proteostasi particip hit-cf way expand
address patient popul acceler european approv
phase trial protestasi conduct phase ii studi
random homozyg heterozyg patient doublet
posenacaftor potenti dirocaftor corrector triplerx
posenacaftor dirocaftor nesolicaftor amplifi placebo
triplerx benefit homozyg patient
sweat chlorid reduct pool placebo group day
patient poor respond vertex cftr modul achiev
day proteostasi initi phase trial later year
depend fund
cf competit space proteostasi drug may fail clinic gain regulatori
proteostasi develop drug treat cystic fibrosi
proj ev cash
march
piper sandler seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
remain overweight howev lower price target base delay
initi phase trial push fda approv proteostasi
proprietari triplerx approv addit roll forward discount period
lower price target base project enterpris valu
million million
anticip proteostasi initi phase trial later year
depend upon fund result push anticip triplerx approv
form valu proteostasi proprietari triplerx regimen million
appli standard multipl sale million discount back
prior valu triplerx sale million appli multipl
sale million discount back continu project
similar penetr vertex non-respond one year later
continu anticip european triplerx approv base phase choic
trial although conced could prove conserv valu triplerx cf sale europ
million appli multipl sale million discount back
prior valu triplerx cf sale europ million appli multipl
sale million discount back trim
proteostasi triplerx sale europ penetr result
vertex recent reimburs agreement near-term trikafta approv europ
proteostasi end cash million add cash million vs
prior net cash million proteostasi push initi phase
trial guid current cash fund oper divid decreas
project market cap million million share arriv lower price
target pleas see exhibit
piper sandler compani estim
page
thousand except per share
research develop
gener administr
compani report piper sandler estim
current disclosur inform compani found
